BI 765063

ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal
Fierce Biotech
Fri, 05/21/21 - 11:52 am
Boehringer Ingelheim
OSE Immunotherapeutics
immuno-oncology
BI 765063
ASCO 2021
Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody
Pharmaceutical Business Review
Tue, 06/18/19 - 09:56 am
Boehringer Ingelheim
OSE Immuotherapeutics
clinical trials
BI 765063
solid tumors